Celanese Corp (CE) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Celanese Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Celanese is a global chemical and specialty materials company operating through two primary segments: Engineered Materials (high-performance polymers for automotive, medical, and electronics) and the Acetyl Chain (integrated acetyl products, acetate tow, and emulsion polymers). The company employs approximately 11,434 people globally across 51 production facilities.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $9.54 billion | $10.27 billion | (7.0%) |
| Gross Profit | $1.95 billion | $2.34 billion | (16.4%) |
| Operating Loss | $(0.79) billion | $(0.72) billion | (9.2%) |
| Net Loss (Attributable to Celanese) | $(1.17) billion | $(1.54) billion | Improvement of $0.38B |
| Operating Margin | (8.2%) | (7.0%) | -120 bps |
| Cash and Cash Equivalents | $1.26 billion | $0.96 billion | +31.2% |
| Total Debt | $12.60 billion | $12.58 billion | Flat |
| Operating Cash Flow | $1.15 billion | $0.97 billion | +18.7% |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 7% due to lower volumes in both segments driven by weaker global economic conditions and lower pricing in the Acetyl Chain segment due to oversupply.
- Significant Impairments: The company recorded non-cash impairment losses totaling $1.49 billion in 2025, primarily within the Engineered Materials segment. This includes a $1.14 billion goodwill impairment and a $346 million impairment of indefinite-lived intangible assets (primarily the Zytel trade name). These were driven by a decline in market capitalization and increased discount rates.
- Cost Reductions: Operating loss widened slightly, but was mitigated by $195 million in cost savings and synergy realizations, lower raw material costs, and a $172 million reduction in impairment charges compared to 2024.
- Plant Closures: The company announced the intended closure of its Lanaken, Belgium facility (Acetyl Chain), expecting $140 million in exit costs through 2027. Operations at the Mechelen, Belgium facility ceased in 2024.
- Dividend Reduction: As part of deleveraging efforts, the quarterly dividend was reduced by approximately 95% starting in Q1 2025.
Guidance, Outlook, and Risks
- Deleveraging Strategy: Management is prioritizing debt reduction. The share repurchase program has been paused. The company completed the sale of the Micromax business for $492 million in February 2026.
- Covenant Compliance Risk: The company notes it may be unable to comply with the consolidated leverage ratio covenant under its U.S. Revolving Credit Facility starting in Q1 2026 without implementing mitigation strategies (e.g., amendments, waivers, or further divestitures).
- Capital Expenditures: 2025 CapEx was $343 million. The company expects 2026 CapEx to range between $300 million and $350 million, focused on maintenance and productivity.
- Legal and Regulatory: The company faces ongoing antitrust claims related to a 2020 European Commission settlement regarding ethylene purchases, with new claims filed in 2025 and 2026. Additionally, the company is subject to evolving climate change regulations and tax audits in multiple jurisdictions (U.S., Germany, Netherlands).
- Market Risks: Significant exposure to raw material price volatility (ethylene, methanol, natural gas) and foreign currency fluctuations (Euro, Chinese Yuan).
Investor Verification Checklist
- Debt Covenants: Verify the status of negotiations regarding the U.S. Revolving Credit Facility leverage ratio covenant effective Q1 2026.
- Impairment Sustainability: Assess whether the $1.49 billion in impairments resolves the valuation gap for Engineered Materials or if further write-downs are likely given the current market cap.
- Liquidity Position: Confirm the sufficiency of the $1.26 billion cash balance and $1.75 billion available credit line to service $12.6 billion in debt amidst operating losses.
- Dividend Policy: Monitor for any further reductions or suspensions of the dividend as the company executes its deleveraging plan.
- Antitrust Exposure: Track the progress of the 11 new antitrust claims filed in 2025/2026 related to the ethylene price-fixing settlement.